Insider Trading activities of Dexcom Inc insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Dexcom Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Dexcom Inc since year 2005. Table 2 shows the detailed insider transactions of Dexcom Inc since 2005. The reporting company's ticker symbol is DXCM. The reporting company's CIK number is 1093557.
The total value of stock buying since 2005 is $6,467,394.
The total value of stock sales since 2005 is $539,748,592.
The total value of stock option exercises since 2005 is $34,498,305.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Dexcom Inc (DXCM).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-11 35,000 $1,746,350 0 $0 0 $0
2017-10 0 $0 1,635 $73,274 0 $0
2017-09 0 $0 12,329 $865,783 0 $0
2017-08 0 $0 14,866 $1,072,656 0 $0
2017-07 0 $0 10,650 $760,867 0 $0
2017-06 0 $0 13,837 $998,052 0 $0
2017-05 0 $0 16,481 $1,137,953 33,649 $237,574
2017-04 0 $0 32,832 $2,469,199 10,000 $87,899
2017-03 0 $0 95,976 $7,455,791 52,390 $404,789
2017-02 0 $0 42,615 $3,412,745 34,627 $326,393
2017-01 0 $0 84,031 $6,496,372 77,837 $662,044
2016-12 0 $0 15,624 $1,002,531 10,000 $76,100
2016-11 0 $0 16,899 $1,161,177 0 $0
2016-10 0 $0 47,510 $3,927,959 11,000 $83,930
2016-09 0 $0 125,242 $11,708,480 16,999 $107,506
2016-08 0 $0 328,552 $29,928,996 87,004 $696,904
2016-07 0 $0 93,885 $7,818,709 42,000 $276,060
2016-06 0 $0 368,568 $27,559,316 180,000 $620,200
2016-05 0 $0 99,002 $6,242,405 20,000 $196,000
2016-04 0 $0 63,971 $4,468,386 20,000 $155,800
2016-03 0 $0 38,696 $2,392,252 0 $0
2016-02 0 $0 3,560 $222,500 0 $0
2016-01 0 $0 33,295 $2,530,624 0 $0
2015-12 0 $0 85,119 $7,185,230 59,000 $407,960
2015-11 0 $0 256,142 $21,784,051 211,001 $1,638,808
2015-10 0 $0 50,420 $4,058,170 20,000 $196,000
2015-09 0 $0 247,099 $23,468,733 190,000 $1,283,223
2015-08 0 $0 145,601 $13,755,602 48,392 $390,485
2015-07 0 $0 176,661 $14,537,192 70,000 $705,930
2015-06 0 $0 175,552 $12,785,157 106,316 $744,932
2015-05 0 $0 371,989 $25,494,868 245,640 $1,461,838
2015-04 0 $0 166,448 $11,174,822 114,758 $1,498,909
2015-03 0 $0 186,159 $11,278,347 122,283 $1,445,564
2015-02 0 $0 79,253 $4,928,395 62,327 $569,108
2015-01 0 $0 119,210 $7,008,248 102,284 $967,219
2014-12 0 $0 159,079 $8,658,835 120,750 $833,925
2014-11 0 $0 375,636 $19,543,412 364,308 $3,158,163
2014-10 0 $0 100,400 $4,117,198 88,750 $639,845
2014-09 0 $0 100,518 $4,179,277 94,250 $600,715
2014-08 0 $0 473,494 $21,016,505 412,520 $3,031,108
2014-07 0 $0 130,500 $4,917,044 88,750 $602,365
2014-06 0 $0 164,500 $6,382,583 92,750 $621,665
2014-05 0 $0 134,957 $3,892,614 96,957 $513,161
2014-04 0 $0 129,884 $4,743,973 100,311 $600,512
2014-03 0 $0 448,985 $20,563,258 443,677 $3,670,026
2014-02 0 $0 280,925 $12,452,842 220,925 $1,592,280
2014-01 0 $0 93,000 $3,406,019 83,000 $578,470
2013-12 0 $0 210,130 $7,162,226 246,090 $1,456,943
2013-11 0 $0 197,322 $6,463,260 154,522 $690,993
2013-10 0 $0 9,000 $251,910 0 $0
2013-09 0 $0 9,000 $243,000 0 $0
2013-08 0 $0 9,000 $199,350 0 $0
2013-07 0 $0 9,000 $205,812 0 $0
2013-06 0 $0 46,361 $1,011,909 10,000 $24,000
2013-05 0 $0 60,272 $1,149,340 50,000 $123,950
2013-04 0 $0 9,000 $152,118 0 $0
2013-03 70,000 $1,085,000 58,070 $928,445 15,416 $7,708
2013-02 0 $0 75,000 $1,123,300 75,000 $239,250
2013-01 0 $0 9,000 $125,010 0 $0
2012-12 0 $0 68,347 $956,515 10,000 $31,900
2012-11 0 $0 5,000 $63,800 0 $0
2012-10 0 $0 5,000 $74,650 0 $0
2012-09 0 $0 24,000 $323,400 0 $0
2012-08 0 $0 36,249 $462,967 0 $0
2012-07 0 $0 5,000 $65,155 0 $0
2012-06 0 $0 17,077 $182,818 0 $0
2012-05 0 $0 19,198 $198,227 28,466 $14,233
2012-04 0 $0 5,000 $53,175 0 $0
2012-03 2,000 $20,710 5,000 $51,550 0 $0
2012-02 0 $0 5,000 $58,545 0 $0
2012-01 0 $0 5,000 $47,650 0 $0
2011-12 2,000 $16,068 0 $0 0 $0
2011-11 8,000 $56,760 0 $0 0 $0
2011-09 2,000 $24,708 0 $0 0 $0
2010-11 2,400 $28,449 0 $0 0 $0
2010-06 5,000 $50,250 0 $0 0 $0
2010-05 65,000 $690,779 0 $0 6,606 $46,109
2010-03 0 $0 10,000 $97,920 0 $0
2009-11 20,000 $143,768 0 $0 0 $0
2009-10 0 $0 0 $0 3,861 $24,440
2009-08 5,000 $34,225 0 $0 0 $0
2009-05 27,500 $103,660 0 $0 0 $0
2009-03 70,800 $285,075 0 $0 0 $0
2008-11 188,750 $336,279 0 $0 0 $0
2008-08 10,000 $66,700 0 $0 0 $0
2008-03 247,000 $1,205,523 0 $0 0 $0
2007-08 0 $0 3,296 $23,401 0 $0
2007-03 0 $0 4,000 $28,700 0 $0
2006-12 0 $0 17,363 $203,164 0 $0
2006-07 3,000 $33,600 0 $0 0 $0
2006-06 0 $0 0 $0 53,125 $21,250
2006-05 0 $0 3,482,500 $83,580,000 172,500 $56,500
2006-03 0 $0 40,648 $748,424 46,614 $23,307
2006-02 0 $0 0 $0 14,375 $4,312
2006-01 0 $0 0 $0 100,000 $50,000
2005-12 0 $0 4,000 $58,348 0 $0
2005-11 0 $0 2,333,900 $31,053,551 0 $0
2005-10 0 $0 611,000 $7,362,550 0 $0
2005-08 9,950 $101,490 0 $0 0 $0
2005-04 36,500 $438,000 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Dexcom Inc insiders (DXCM)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-11-07 Altman Steven R (Director) Buy 25,000 50.01 1,250,250
2017-11-06 Altman Steven R (Director) Buy 10,000 49.61 496,100
2017-10-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 1,635 44.82 73,274
2017-09-25 Doubleday Richard (EVP, Chief Commercial Officer) Sale 1,635 69.77 114,080
2017-09-25 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 1,450 69.81 101,218
2017-09-20 Sayer Kevin R (President & CEO) Sale 6,000 69.34 416,045
2017-09-11 Balo Andrew K (EVP, Reg. Strategy, Clinical) Sale 3,244 72.27 234,440
2017-08-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 1,635 75.26 123,053
2017-08-23 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 3,987 75.26 300,045
2017-08-11 Sayer Kevin R (President & CEO) Sale 6,000 69.77 418,638
2017-08-10 Balo Andrew K (EVP, Reg. Strategy, Clinical) Sale 3,244 71.18 230,920
2017-07-24 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 1,450 69.47 100,724
2017-07-12 Sayer Kevin R (President & CEO) Sale 6,000 71.86 431,171
2017-07-10 Balo Andrew K (EVP, Reg. Strategy, Clinical) Sale 3,200 71.55 228,972
2017-06-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 3,187 78.22 249,274
2017-06-23 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 1,450 78.19 113,376
2017-06-12 Balo Andrew K (EVP, Clinical and Regulatory) Sale 3,200 69.06 220,988
2017-06-12 Sayer Kevin R (President & CEO) Sale 6,000 69.07 414,414
2017-05-24 Gregg Terrance H (Executive Chairman) Option Ex 30,000 6.85 205,500
2017-05-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 3,182 68.29 217,289
2017-05-23 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 1,450 68.24 98,949
2017-05-17 Sayer Kevin R (President & CEO) Sale 8,649 68.39 591,539
2017-05-17 Sayer Kevin R (President & CEO) Option Ex 3,649 8.79 32,074
2017-05-10 Balo Andrew K (EVP, Clinical and Regulatory) Sale 3,200 71.93 230,176
2017-04-24 Doubleday Richard (EVP, Chief Commercial Officer) Sale 3,182 75.78 241,131
2017-04-24 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 1,450 75.89 110,040
2017-04-20 Gregg Terrance H (Executive Chairman) Sale 15,000 74.10 1,111,500
2017-04-17 Sayer Kevin R (President & CEO) Sale 10,000 75.63 756,320
2017-04-17 Sayer Kevin R (President & CEO) Option Ex 10,000 8.79 87,899
2017-04-10 Balo Andrew K (EVP, Clinical and Regulatory) Sale 3,200 78.19 250,208
2017-03-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 3,182 76.38 243,028
2017-03-23 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 3,987 76.25 304,004
2017-03-22 Roper Jess (SVP, CFO) Sale 2,000 75.97 151,936
2017-03-17 Sayer Kevin R (President & CEO) Sale 10,000 77.82 778,160
2017-03-17 Sayer Kevin R (President & CEO) Option Ex 10,000 8.79 87,899
2017-03-14 Leach Jacob Steven (SVP, Research & Development) Sale 3,050 77.32 235,825
2017-03-14 Kahn Barbara (Director) Sale 3,000 77.36 232,080
2017-03-13 Leach Jacob Steven (SVP, Research & Development) Sale 7,926 77.92 617,625
2017-03-13 Valdes Jorge A (CTO) Sale 14,400 77.74 1,119,513
2017-03-10 Leach Jacob Steven (SVP, Research & Development) Option Ex 7,500 7.63 57,225
2017-03-10 Balo Andrew K (EVP, Clinical and Regulatory) Sale 3,200 77.71 248,671
2017-03-09 Leach Jacob Steven (SVP, Research & Development) Sale 10,341 77.40 800,383
2017-03-09 Lister John (General Manager, EMEA) Sale 3,000 77.67 233,001
2017-03-09 Lister John (General Manager, EMEA) Option Ex 3,000 8.85 26,550
2017-03-06 Skyler Jay S (Director) Sale 31,890 78.13 2,491,565
2017-03-06 Skyler Jay S (Director) Option Ex 31,890 7.31 233,115
2017-02-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 3,182 78.42 249,529
2017-02-22 Roper Jess (SVP, CFO) Sale 2,333 78.77 183,758
2017-02-17 Sayer Kevin R (President & CEO) Sale 10,000 81.62 816,180
2017-02-17 Sayer Kevin R (President & CEO) Option Ex 10,000 8.79 87,899
2017-02-10 Balo Andrew K (EVP, Clinical and Regulatory) Sale 3,200 79.30 253,760
2017-02-10 Balo Andrew K (EVP, Clinical and Regulatory) Option Ex 727 9.80 7,124
2017-02-09 Lister John (General Manager, EMEA) Sale 3,000 79.73 239,205
2017-02-09 Lister John (General Manager, EMEA) Option Ex 3,000 8.85 26,550
2017-02-09 Valdes Jorge A (CTO) Sale 7,000 79.76 558,313
2017-02-09 Valdes Jorge A (CTO) Option Ex 7,000 9.80 68,600
2017-02-01 Valdes Jorge A (CTO) Sale 13,900 80.00 1,112,000
2017-02-01 Valdes Jorge A (CTO) Option Ex 13,900 9.80 136,220
2017-01-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 3,182 79.50 252,978
2017-01-23 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 9,637 80.00 770,911
2017-01-23 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Option Ex 9,637 7.79 75,072
2017-01-18 Roper Jess (SVP, CFO) Sale 3,012 85.01 256,050
2017-01-17 Sayer Kevin R (President & CEO) Sale 10,000 85.94 859,360
2017-01-17 Sayer Kevin R (President & CEO) Option Ex 10,000 8.79 87,899
2017-01-13 Lister John (General Manager, EMEA) Sale 15,000 79.36 1,190,400
2017-01-13 Lister John (General Manager, EMEA) Option Ex 15,000 8.85 132,750
2017-01-13 Valdes Jorge A (CTO) Sale 26,100 80.00 2,088,000
2017-01-13 Valdes Jorge A (CTO) Option Ex 26,100 9.08 236,909
2017-01-10 Balo Andrew K (EVP, Clinical and Regulatory) Sale 3,200 62.86 201,152
2017-01-10 Balo Andrew K (EVP, Clinical and Regulatory) Option Ex 3,200 9.80 31,360
2017-01-09 Lister John (General Manager, EMEA) Sale 3,000 63.02 189,045
2017-01-09 Lister John (General Manager, EMEA) Option Ex 3,000 8.85 26,550
2017-01-09 Valdes Jorge A (CTO) Sale 10,900 63.16 688,476
2017-01-09 Valdes Jorge A (CTO) Option Ex 10,900 6.56 71,504
2016-12-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 3,182 62.17 197,831
2016-12-14 Roper Jess (SVP, CFO) Sale 2,442 64.14 156,620
2016-12-09 Valdes Jorge A (CTO) Sale 10,000 64.81 648,080
2016-12-09 Valdes Jorge A (CTO) Option Ex 10,000 7.61 76,100
2016-11-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 3,182 70.19 223,350
2016-11-23 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 10,300 70.32 724,265
2016-11-09 Lister John (General Manager, EMEA) Sale 3,417 62.50 213,562
2016-10-24 Doubleday Richard (EVP, Chief Commercial Officer) Sale 3,182 81.12 258,111
2016-10-24 Roper Jess (SVP, CFO) Sale 2,471 80.75 199,545
2016-10-24 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 10,300 81.95 844,064
2016-10-19 Balo Andrew K (EVP, Clinical and Regulatory) Sale 4,997 82.31 411,303
2016-10-14 Sayer Kevin R (President & CEO) Sale 7,000 81.87 573,104
2016-10-10 Lister John (General Manager, EMEA) Sale 3,560 84.41 300,506
2016-10-10 Valdes Jorge A (CTO) Sale 11,000 84.42 928,576
2016-10-10 Valdes Jorge A (CTO) Option Ex 11,000 7.63 83,930
2016-10-05 Balo Andrew K (EVP, Clinical and Regulatory) Sale 5,000 82.55 412,750
2016-09-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 3,182 93.97 298,999
2016-09-23 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 10,300 94.00 968,200
2016-09-22 Roper Jess (SVP, CFO) Sale 2,470 93.99 232,155
2016-09-21 Balo Andrew K (EVP, Clinical and Regulatory) Sale 5,000 92.87 464,365
2016-09-14 Sayer Kevin R (President & CEO) Sale 7,000 91.79 642,530
2016-09-12 Kahn Barbara (Director) Sale 5,000 92.90 464,510
2016-09-12 Valdes Jorge A (CTO) Sale 7,071 92.06 650,963
2016-09-12 Skyler Jay S (Director) Sale 10,000 93.00 930,000
2016-09-09 Lister John (General Manager, EMEA) Sale 7,120 93.65 666,780
2016-09-09 Valdes Jorge A (CTO) Sale 12,000 93.66 1,123,908
2016-09-09 Valdes Jorge A (CTO) Option Ex 12,000 7.63 91,560
2016-09-09 Skyler Jay S (Director) Sale 25,000 94.07 2,351,800
2016-09-08 Gregg Terrance H (Executive Chairman) Sale 5,145 95.59 491,831
2016-09-07 Balo Andrew K (EVP, Clinical and Regulatory) Sale 4,999 94.45 472,155
2016-09-07 Balo Andrew K (EVP, Clinical and Regulatory) Option Ex 4,999 3.19 15,946
2016-09-07 Foletta Mark G (Director) Sale 1,800 94.62 170,325
2016-09-07 Gregg Terrance H (Executive Chairman) Sale 5,595 95.01 531,569
2016-09-01 Lord Jonathan T Md (Director) Sale 10,000 91.50 915,000
2016-08-30 Gregg Terrance H (Executive Chairman) Sale 10,000 92.14 921,360
2016-08-24 Balo Andrew K (EVP, Clinical and Regulatory) Sale 5,000 91.72 458,600
2016-08-24 Balo Andrew K (EVP, Clinical and Regulatory) Option Ex 5,000 3.19 15,950
2016-08-24 Gregg Terrance H (Executive Chairman) Sale 10,000 92.72 927,150
2016-08-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 3,182 90.89 289,224
2016-08-23 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 10,300 90.74 934,591
2016-08-23 Gregg Terrance H (Executive Chairman) Sale 10,000 91.11 911,120
2016-08-22 Gregg Terrance H (Executive Chairman) Sale 10,000 90.51 905,110
2016-08-19 Gregg Terrance H (Executive Chairman) Sale 20,000 90.63 1,812,520
2016-08-19 Skyler Jay S (Director) Sale 25,000 90.77 2,269,225
2016-08-19 Altman Steven R (Director) Sale 3,500 90.91 318,178
2016-08-18 Gregg Terrance H (Executive Chairman) Sale 20,000 90.77 1,815,320
2016-08-15 Sayer Kevin R (President & CEO) Sale 7,000 90.78 635,474
2016-08-15 Gregg Terrance H (Executive Chairman) Sale 14,942 91.01 1,359,856
2016-08-12 Lord Jonathan T Md (Director) Sale 5,000 90.50 452,505
2016-08-11 Gregg Terrance H (Executive Chairman) Sale 10,900 91.03 992,281
2016-08-11 Lord Jonathan T Md (Director) Sale 5,000 90.78 453,895
2016-08-10 Balo Andrew K (EVP, Clinical and Regulatory) Sale 5,000 90.26 451,300
2016-08-10 Balo Andrew K (EVP, Clinical and Regulatory) Option Ex 5,000 3.19 15,950
2016-08-09 Lister John (General Manager, EMEA) Sale 3,560 91.07 324,216
2016-08-09 Valdes Jorge A (CTO) Sale 32,000 91.06 2,913,984
2016-08-09 Valdes Jorge A (CTO) Option Ex 32,000 7.63 244,160
2016-08-09 Sayer Kevin R (President & CEO) Sale 20,000 90.98 1,819,560
2016-08-09 Sayer Kevin R (President & CEO) Option Ex 20,000 8.79 175,799
2016-08-09 Gregg Terrance H (Executive Chairman) Sale 37,168 91.05 3,384,220
2016-08-08 Kahn Barbara (Director) Sale 6,000 90.52 543,132
2016-08-08 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Option Ex 4 11.33 45
2016-08-05 Valdes Jorge A (CTO) Sale 25,000 91.22 2,280,375
2016-08-05 Valdes Jorge A (CTO) Option Ex 25,000 9.80 245,000
2016-08-05 Gregg Terrance H (Executive Chairman) Sale 20,000 91.29 1,825,800
2016-08-01 Moy Jeffrey (SVP, Operations) Sale 10,000 93.00 930,000
2016-07-29 Moy Jeffrey (SVP, Operations) Sale 5,000 91.00 455,000
2016-07-27 Balo Andrew K (EVP, Clinical and Regulatory) Sale 5,000 88.14 440,700
2016-07-27 Balo Andrew K (EVP, Clinical and Regulatory) Option Ex 5,000 3.19 15,950
2016-07-25 Doubleday Richard (EVP, Chief Commercial Officer) Sale 3,182 87.31 277,820
2016-07-25 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 10,300 87.33 899,478
2016-07-22 Moy Jeffrey (SVP, Operations) Sale 10,000 88.48 884,800
2016-07-19 Moy Jeffrey (SVP, Operations) Sale 12,843 84.00 1,078,812
2016-07-13 Balo Andrew K (EVP, Clinical and Regulatory) Sale 5,000 80.12 400,600
2016-07-13 Balo Andrew K (EVP, Clinical and Regulatory) Option Ex 5,000 3.19 15,950
2016-07-13 Sayer Kevin R (President & CEO) Sale 7,000 79.92 559,454
2016-07-11 Lister John (General Manager, EMEA) Sale 3,560 79.35 282,493

Insider trading activities including stock purchases, stock sales, and option exercises of DXCM listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Dexcom Inc (symbol DXCM, CIK number 1093557) see the Securities and Exchange Commission (SEC) website.